CN116585432B - 一种药物组合物及其制备方法与在制备解毒益肾药物中的应用 - Google Patents
一种药物组合物及其制备方法与在制备解毒益肾药物中的应用 Download PDFInfo
- Publication number
- CN116585432B CN116585432B CN202310750510.XA CN202310750510A CN116585432B CN 116585432 B CN116585432 B CN 116585432B CN 202310750510 A CN202310750510 A CN 202310750510A CN 116585432 B CN116585432 B CN 116585432B
- Authority
- CN
- China
- Prior art keywords
- parts
- kidney
- pharmaceutical composition
- filtrate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003734 kidney Anatomy 0.000 title claims abstract description 69
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title description 14
- 241000237502 Ostreidae Species 0.000 claims abstract description 18
- 235000004347 Perilla Nutrition 0.000 claims abstract description 18
- 235000020636 oyster Nutrition 0.000 claims abstract description 18
- 210000003608 fece Anatomy 0.000 claims abstract description 17
- 241000301400 Trogopterus Species 0.000 claims abstract description 16
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 15
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 15
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 15
- 244000291333 Serissa japonica Species 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- 240000004980 Rheum officinale Species 0.000 claims abstract description 13
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 13
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 12
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 12
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 12
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 12
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 12
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 12
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 12
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 87
- 230000034994 death Effects 0.000 claims description 43
- 229910052742 iron Inorganic materials 0.000 claims description 43
- 210000004926 tubular epithelial cell Anatomy 0.000 claims description 35
- 230000006378 damage Effects 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 28
- 208000020832 chronic kidney disease Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 12
- 238000001784 detoxification Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000052 vinegar Substances 0.000 claims description 10
- 235000021419 vinegar Nutrition 0.000 claims description 10
- 230000003907 kidney function Effects 0.000 claims description 9
- 241000209020 Cornus Species 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 241000219061 Rheum Species 0.000 claims description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 229940107666 astragalus root Drugs 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 241001573366 Astragalus membranaceus Species 0.000 claims 2
- 239000003053 toxin Substances 0.000 abstract description 28
- 231100000765 toxin Toxicity 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 14
- 241000045403 Astragalus propinquus Species 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 3
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 61
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 49
- 108700012359 toxins Proteins 0.000 description 26
- 241000700159 Rattus Species 0.000 description 21
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 20
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 16
- 229930024421 Adenine Natural products 0.000 description 15
- 206010016654 Fibrosis Diseases 0.000 description 15
- 229960000643 adenine Drugs 0.000 description 15
- 230000004761 fibrosis Effects 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- 229960001231 choline Drugs 0.000 description 13
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 13
- 208000037888 epithelial cell injury Diseases 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 101100173542 Caenorhabditis elegans fer-1 gene Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- UJHBVMHOBZBWMX-UHFFFAOYSA-N ferrostatin-1 Chemical compound NC1=CC(C(=O)OCC)=CC=C1NC1CCCCC1 UJHBVMHOBZBWMX-UHFFFAOYSA-N 0.000 description 7
- 230000007946 glucose deprivation Effects 0.000 description 7
- 208000017169 kidney disease Diseases 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229940045835 RSL3 Drugs 0.000 description 6
- 229940009456 adriamycin Drugs 0.000 description 6
- 238000010201 enrichment analysis Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- TXJZRSRTYPUYRW-NQIIRXRSSA-N methyl (1s,3r)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate Chemical compound C1([C@H]2C3=C(C4=CC=CC=C4N3)C[C@@H](N2C(=O)CCl)C(=O)OC)=CC=C(C(=O)OC)C=C1 TXJZRSRTYPUYRW-NQIIRXRSSA-N 0.000 description 6
- 239000012452 mother liquor Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 5
- 231100000417 nephrotoxicity Toxicity 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 206010029155 Nephropathy toxic Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 230000007694 nephrotoxicity Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010013647 Drowning Diseases 0.000 description 2
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 241001404789 Smilax glabra Species 0.000 description 2
- 240000001398 Typha domingensis Species 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000002441 uremic toxin Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000605422 Asparagus asparagoides Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000307676 Diploprion bifasciatum Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000004224 Typha angustifolia Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000002933 hypercholinergic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种药物组合物及其制备方法与在制备解毒益肾药物中的应用,所述药物组合物由如下重量份数的中药组分制成:紫苏叶29~37份,茵陈12.5~20.5份,醋五灵脂7~15份,炒蒲黄7~15份,六月雪18~26份,土茯苓29~37份,红花7~15份,酒大黄4.8~12.8份,牡蛎29~37份,茯苓7~15份,黄芪29~37份,酒萸肉7~15份。本发明所提供的药物组合物具有解毒益肾、清利和络之功,使肾毒得解,瘀滞得通,气血调和,邪退正安,可以有效用于制备解毒益肾药物。
Description
技术领域
本发明涉及中药领域,具体涉及一种药物组合物及其制备方法与在制备解毒益肾药物中的应用。
背景技术
“毒”的概念最早可以溯源于《黄帝内经》,指出了毒邪是有别于六淫的一种特殊病因。历代医家结合临床经验对毒邪的致病机理形成了初步的认识。现代中医肾脏病学奠基人邹云翔教授在临床上首创中药复方解毒疗法以抢救尿毒症患者,国医大师邹燕勤教授继承邹老肾脏病辨治理念,进一步拓展了解毒类中药在各种慢性肾脏疾病中的应用。申报人师承邹燕勤教授,在“解毒法”治疗肾脏病的基础上,结合CKD的发病机理和临床多年的诊疗经验,系统性地提出了从“肾毒”论治CKD的观点,肾毒内蕴、肾络受损是CKD各阶段的基本病机。
肾毒既是CKD的致病因素也是重要的病理产物。肾元不足存于内,诸源之邪攻于外,内外相引,伏蕴于肾,化为肾毒,不断耗伤肾脏精气,损伤肾络,破坏肾脏正常的生理功能,导致了CKD的发生。肾开窍于耳及二阴,脏腑失调,肾失所司,藏泄失度,则使内生浊邪不得随二便而解,潴留体内,复生肾毒,亦即“溺毒”,而“溺毒入血”也是CKD尿毒症毒素的主要来源。临床可表现为血清肌酐、尿素氮及肠道菌群代谢产物(如TMAO)等浓度的异常升高。
肾毒与CKD相互推动演化,肾病内生肾毒,肾毒反伤肾气,使藏泄之用愈弱,循环往复,使毒邪愈盛,病势愈深,推动了CKD的持续进展。若日久失治,毒邪深重,阴阳耗衰,最终可形成固缩肾。此亦与本病病程中尿毒症毒素的逐渐积累,肾功能进展性下降,最终发展为终末期肾病的病理演变过程相吻合。肾毒还可夹挟湿、热、痰、瘀等,蔓延侵袭,随处可至,是CKD并发症多发,尤其是心血管事件高发的根本原因。可见,肾毒既可以指邪气,亦可以是本病过程中蓄积于内损害机体的代谢产物,不仅参与诱导了CKD的发生,更是CKD不断进展、迁延难愈、变证丛生的关键。
发明内容
发明目的:本发明所要解决的技术问题是针对现有技术的不足,提供一种药物组合物及其制备方法与在制备解毒益肾药物中的应用。
发明思路:基于“肾毒”理论,申请人认为在CKD的各阶段治疗中,益肾元是基础,解肾毒是关键。尤其在CKD早中期更需重视肾毒在疾病进展中的推动作用,及时干预,既病防变。其中“解肾毒”可以减轻浊毒对于全身脏腑精气的耗伤,恢复气血津液正常的运行输布,缓解患者的各项临床症状。而益肾元则通过充养耗损已久的肾气,提高机体抵抗病邪和自我修复的能力,改善患者的临床预后。故在CKD临床治疗中当以“益肾解毒”为大法,祛毒扶正,标本兼治,方能切实缓解疾病进展,提高患者的生活质量,改善预后。申报人在“肾毒”致病和“解肾毒”保肾的理论基础上,结合20余年的临床经验,最终总结形成了本发明的药物组合物。
为了解决上述技术问题,本发明公开了如下技术方案:
第一方面,本发明公开了一种药物组合物,由如下中药组分制成:紫苏叶、茵陈、醋五灵脂、炒蒲黄、六月雪、土茯苓、红花、酒大黄、牡蛎、茯苓、黄芪、酒萸肉或山茱萸。
本发明中所述五灵脂,若无特色说明均为醋五灵脂;本发明中所述蒲黄,若无特殊说明均为炒蒲黄;本发明中所述大黄,若无特殊说明均为酒大黄。
本发明中所述组合物由中紫苏叶为气中血药,能温散血中毒邪,和胃降逆;茵陈其体轻清,疏通为之用,与苏叶相合,共达调和气血、清利湿热、解毒降浊之功,故二者共为君药。土茯苓味甘淡性平,具有解毒除湿的作用,六月雪味苦性凉,亦有清热解毒除湿之功,二药均有下降之势,相须为用,能够利湿泄浊,清热解毒,疏通经络,共为臣药,可以进一步加强本方解湿热之毒的功效;且二药均甘淡和缓,亦切合邹氏肾科和缓平淡的用药主张。在组方中加入红花、失笑散(五灵脂、蒲黄组成)作为臣药,以活血祛瘀,同时还有部分解毒之功。制大黄性寒味苦,可以泻下攻积,清热解毒,同时还有活血化瘀之功;牡蛎性凉味咸,可以软坚散结、安神涩精;大黄可以祛瘀通络,荡涤浊毒,降低血清毒素水平;牡蛎可以软化硬化之肾脏,消散顽痰,吸附血液中的毒素;二药合用可以消散肾中沉积顽固的痰浊瘀毒,毒邪得化则新血得生,同时,牡蛎还可以制约大黄的泻下之力,从而祛邪而不伤正。另外,本方选择加入了黄芪、酒萸肉或山茱萸和茯苓作为佐药,此皆为性味平和之品,在补益肾中精气的同时兼顾补养脾胃,一方面可以通过充养后天以补先天,另一方面由于本病常伴有脾胃功能的减退,脾胃功能的健运更能充分运化各种药物,从而发挥更好的治疗效果。诸药合用,共达解毒益肾、清利和络之功,使肾毒得解,瘀滞得通,气血调和,邪退正安。
【功能主治】解毒益肾,清利和络。用于慢性肾衰竭各期毒瘀阻络证,症见:下肢浮肿,腰酸乏力,夜尿增多或尿量减少,恶心呕吐,头晕头痛,心悸胸闷,手足抽筋,骨节疼痛,面色黧黑或白光白,舌淡或暗,伴瘀斑瘀点,苔腻,脉沉弦。
在一些实施例中,各中药组分的重量份数如下:紫苏叶29~37份,茵陈12.5~20.5份,醋五灵脂7~15份,炒蒲黄7~15份,六月雪18~26份,土茯苓29~37份,红花7~15份,酒大黄4.8~12.8份,牡蛎29~37份,茯苓7~15份,黄芪29~37份,酒萸肉或山茱萸7~15份;在一些实施例中,各中药组分的重量份数如下:紫苏叶31~35份,茵陈12.5~20.5份,醋五灵脂7~15份,炒蒲黄7~15份,六月雪18~26份,土茯苓29~37份,红花7~15份,酒大黄4.8~12.8份,牡蛎29~37份,茯苓7~15份,黄芪29~37份,酒萸肉或山茱萸7~15份;在一些实施例中,各中药组分的重量份数如下:紫苏叶33份,茵陈12.5~20.5份,醋五灵脂7~15份,炒蒲黄7~15份,六月雪18~26份,土茯苓29~37份,红花7~15份,酒大黄4.8~12.8份,牡蛎29~37份,茯苓7~15份,黄芪29~37份,酒萸肉或山茱萸7~15份;在一些实施例中,各中药组分的重量份数如下:紫苏叶31~35份,茵陈14.5~18.5份,醋五灵脂9~13份,炒蒲黄9~13份,六月雪20~24份,土茯苓31~35份,红花9~13份,酒大黄6.8~10.8份,牡蛎31~35份,茯苓9~13份,黄芪31~35份,酒萸肉或山茱萸9~13份;在一些实施例中,各中药组分的重量份数如下:紫苏叶33份,茵陈14.5~18.5份,醋五灵脂9~13份,炒蒲黄9~13份,六月雪20~24份,土茯苓31~35份,红花9~13份,酒大黄6.8~10.8份,牡蛎31~35份,茯苓9~13份,黄芪31~35份,酒萸肉或山茱萸9~13份;在一些实施例中,各中药组分的重量份数如下:紫苏叶33份,茵陈16.5份,醋五灵脂11份,炒蒲黄11份,六月雪22份,土茯苓33份,红花11份,酒大黄8.8份,牡蛎33份,茯苓11份,黄芪33份,酒萸肉或山茱萸11份;在一些实施例中,各中药组分的重量份数如下:紫苏叶33g,茵陈16.5g,醋五灵脂11g,炒蒲黄11g,六月雪22g,土茯苓33g,红花11g,酒大黄8.8g,牡蛎33g,茯苓11g,黄芪33g,酒萸肉或山茱萸11g。
第二方面,本发明公开了上述第一方面中所述药物组合物的制备方法,将各中药组分加水煎煮两次,过滤,所得滤液浓缩。
在一些实施例中,所述制备方法具体为将牡蛎先加水煎煮20~40min,再加入其他各中药组分煎煮30~50min,过滤,得到第一滤液和第一滤渣;所得滤渣再次加水煎煮30~50min,过滤,得到第二滤液和第二滤渣;将第一滤液和第二滤液混合后,再次过滤,得到第三滤液;所得第三滤液蒸发浓缩,得到浓缩液;在一些实施例中,包括如下步骤:所述浓缩液冷冻干燥,得到干粉;在一些实施例中,还包括如下步骤:将所述干粉用PBS缓冲液溶解,再次过滤,得到滤液;在一些实施例中,所述制备方法为将牡蛎先加水煎煮30分钟后再加入其它中药饮片共同煎煮40分钟,过滤后收集滤液,再次加水煎煮40分钟,过滤后收集滤液。混合两次滤液用医用纱布过滤,然后在旋蒸仪以50℃,200转/分进行浓缩;在一些实施例中,所述制备方法具体为将各组分先加药方总质量6~10倍的水煎煮40~80min,再加入1~5倍的水煎煮20~50min,过滤,浓缩;在一些实施例中,浓缩定容至1g/mL。
在一些实施例中,所述浓缩后,浓缩液在-80℃保存。24小时后放置于冷冻干燥机处理,设定真空模式下,0.25mBar,温度为-50℃,最后形冻干成粉状。常规在-20℃冰箱密封保存。称取适量冻干粉,PBS溶解形成处方2提取物母液(1g/mL),然后用0.22μm过滤器进行过滤。过滤后的母液分装后置于-20℃保存。
在一些实施例中,所述制备方法具体为将各中药组分加水煎煮两次,每次30~50min,过滤,合并滤液;所得滤液浓缩至相对密度为1.10~1.20的浓缩液;在一些实施例中,包括如下步骤:将糊精置于流化床中,当物料升温至70~80℃时,开始进液,雾化,干燥,即得;在一些实施例中,所述进液的速度为80~150r/min;所述雾化的外压力为0.15~0.25MPa;所述雾化的内压力为0.1~0.2MPa;在一些实施例中,所述制备方法为以上十二味,加8倍量水煎煮两次,每次40分钟,滤过,滤液合并;减压浓缩(真空度-0.04~-0.08MPa)至相对密度1.10~1.20(60℃),直管式高速离心(转速:16000r/min,流量:4~6L/min);另取糊精置流化床中,设置进风温度为100℃,当物料温度升至70~80℃时,开始进液,进液速度控制在80~150r/min,雾化压力(外0.2MPa,内0.15MPa),制成,喷雾结束后继续干燥,即得。
第三方面,本发明公开了上述第一方面所述药物组合物在制备解毒益肾药物中的应用,或在制备铁死亡诱导剂中的应用。
在一些实施例中,所述应用为在制备防治慢性肾脏病药物中的应用,或在制备防治肾小管上皮细胞损伤药物中的应用,或在制备防治肾小管上皮细胞死亡药物中的应用,或在制备防治肾脏功能恶化药物中的应用,或在制备防治肾脏病理损伤药物中的应用,或在制备防治肾脏铁死亡药物中的应用,或在制备防治肾脏纤维化药物中的应用。
在一些实施例中,所述肾小管上皮细胞损伤或死亡为阿霉素诱导的人肾小管上皮细胞损伤、氧糖剥夺再灌注诱导的人肾小管上皮细胞损伤、TMAO诱导的肾小管上皮细胞损伤/死亡、RSL3诱导的肾小管上皮细胞铁死亡。
在一些实施例中,所述肾脏功能恶化、肾脏病理损伤、肾脏铁死亡、或肾脏纤维化为TMAO诱导的肾脏功能恶化、TMAO诱导的肾脏病理损伤、铁死亡和纤维化、TMAO诱导的肾脏铁死亡、TMAO诱导的肾脏铁死亡及纤维化。
有益效果:与现有技术相比,本发明具有如下优势:
本发明所提供的药物组合物具有解毒益肾、清利和络之功,使肾毒得解,瘀滞得通,气血调和,邪退正安,可以有效用于制备解毒益肾药物。
附图说明
下面结合附图和具体实施方式对本发明做更进一步的具体说明,本发明的上述和/或其他方面的优点将会变得更加清楚。
图1为TMAO干预后的差异蛋白及GO富集分析。
图2为TMAO干预后差异蛋白的KEGG的富集分析。
图3为处方提取物对TMAO损伤模型的蛋白影响及GO富集分析。
图4为处方提取物干预TMAO损伤模型的差异蛋白KEGG富集分析。
图5为TMAO可以诱导NRK-52E细胞损伤。
图6为TMAO诱导NRK-52E细胞铁死亡。
图7为处方提取物可以减轻TMAO诱导的肾小管上皮细胞损伤。
图8为处方提取物可以减轻TMAO诱导的铁死亡。
图9为处方提取物可以减轻RSL3诱导的铁死亡。
图10为处方提取物减轻TMAO诱导的肾脏功能恶化。
图11为处方提取物干预后各组大鼠一般情况变化。
图12为处方提取物干预后各组大鼠Perl’s、Masson染色。
图13为处方提取物干预后各组大鼠铁死亡相关指标变化。
图14为处方提取物干预后各组大鼠铁死亡、纤维化蛋白的表达。
图15为处方提取物可以缓解阿霉素诱导的人肾小管上皮细胞损伤。
图16为处方提取物可以缓解氧糖剥夺再灌注诱导的人肾小管上皮细胞损伤。
具体实施方式
下述实施例中所述实验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径获得。
实施例1中药组合物颗粒的制备
1、处方(所有药物均购自江苏省中医院中药房)
紫苏叶330g茵陈165g醋五灵脂110g炒蒲黄110g六月雪220g
土茯苓330g红花110g酒大黄88g牡蛎330g茯苓110g
黄芪330g酒萸肉110g
以上十二味共制成颗粒1000g,每袋装10g。每1g相当于饮片2.34g。本品用法为一次2~3袋,一日3次,相当于140g~211g饮片,该服用量与临床使用量(一日剂量213g)一致。
2、制法
(1)以上十二味,加8倍质量水煎煮两次,每次40分钟,滤过,滤液合并;减压浓缩(真空度-0.04~-0.08MPa)至相对密度1.10~1.20(60℃),直管式高速离心(转速:16000r/min,流量:4~6L/min)。
(2)另取糊精置流化床中,设置进风温度为100℃,当物料温度升至70~80℃时,开始进液(步骤(1)离心后的液体),进液速度控制在80~150r/min,雾化压力(外0.2MPa,内0.15MPa),制成1000g。喷雾结束后70℃继续干燥1小时,即得。
实施例2中药组合物提取物的制备
配方同实施例1,处方提取物制备流程:称取上述各个中药组分。将牡蛎先加水煎煮30分钟后再加入其它中药饮片共同煎煮40分钟,过滤后收集滤液,再次加水煎煮40分钟,过滤后收集滤液。混合两次滤液用医用纱布过滤,然后在旋蒸仪以50℃,200转/分进行浓缩。浓缩液在-80℃保存。24小时后放置于冷冻干燥机处理,设定真空模式下,0.25mBar,温度为-50℃,最后形冻干成粉状。常规在-20℃冰箱密封保存。称取适量冻干粉,PBS溶解形成处方水提物母液(1g/mL),然后用0.22μm过滤器进行过滤。过滤后的母液分装后置于-20℃保存。
实施例3
处方组成如下:紫苏叶[Folium Perillae]、茵陈[Herba ArtemisiaeScopariae]、六月雪[Serissa japonica Thunb]、土茯苓[Smilax glabra Roxb]、红花[Carthamus tinctorius L]、五灵脂[Faeces Trogopterori]、蒲黄[Typha angustifoliaL]、大黄[Rheum Officinale]、牡蛎[Concha Ostreae]、茯苓[Poria]、黄芪[RadixAstragali]、山茱萸[Cornus officinalis Sieb]。各组分质量比同实施例1。所有药材均采购于江苏省中医院中药房。
按配方比例称取处方饮片,首先加入药方总量8倍水量煎煮1小时,再加3倍水量煎煮半小时,收集中药上清液用医用纱布过滤,然后在旋蒸仪以50℃,200转/分进行浓缩,最后浓缩定容至1g/mL。浓缩液在-80℃保存,24小时后放置于冷冻干燥机处理,设定真空模式下,0.25mBar,温度为-50℃,最后形冻干成粉状。常规在-20℃冰箱密封保存。称取适量冻干粉,PBS溶解形成母液(1g/ml),然后用0.22μm过滤器进行过滤。过滤后的母液分装后置于-20℃保存。
实施例4处方提取物(实施例2)缓解阿霉素诱导的人肾小管上皮细胞损伤
利用阿霉素(ADR)刺激人肾小管上皮细胞HK-2细胞建立损伤模型,筛选处方不同质量浓度的提取物对细胞活性的影响。
体外实验采用人肾小管上皮细胞(HK-2细胞)构建慢性肾脏病损伤模型:用梯度浓度的ADR刺激HK-2细胞诱导肾损伤以模拟慢性肾脏病的肾小管上皮细胞损伤。
根据阿霉素损伤实验表明,选择30μg/mL作为造模剂量。在处方提取物的安全作用质量浓度范围内,给与0.125、0.25、0.5、1、2mg/mL处方提取物,具体为,于倒置相差光学显微镜下观察细胞生长状态,收集处于对数生长期的HK-2细胞,以1×104/孔接种于96孔板中,每孔100μl体系,待24h后细胞达到80%左右开始给药处理。弃旧培养基,每孔加入无血清培养基,或含ADR(30μg·ml-1),或含ADR(30μg·ml-1)+不同质量浓度处方提取物(0.125,0.25,0.5,1,2mg·ml-1)的无血清培养基共孵育24h,干预处理24h后置于倒置光学显微镜下观察细胞形态学变化。
结果如图15所示,我们发现在光镜下阿霉素所诱导HK-2细胞损伤明显缓解。
实施例5处方提取物(实施例2)缓解氧糖剥夺再灌注诱导的人肾小管上皮细胞损伤
利用氧糖剥夺再灌注(OGD/R)刺激人肾小管上皮细胞HK-2细胞建立损伤模型,筛选处方不同质量浓度的提取物对其细胞活性的影响。
建立氧糖剥夺再灌注模型:低氧条件下(1%O2、94%N2、5%CO2)以无糖Earle’s平衡盐液(Earle's BSS,EBSS)培养4h,即为氧糖剥夺(OGD),后再换回含血清的DMEM/F-12完全培养基于正常培养条件下培养1h,即为再灌注。整个过程称为氧糖剥夺再灌注模型(OGD/R),可以模拟动物实验中肾缺血再灌注损伤。
于倒置相差光学显微镜下观察细胞生长状态,收集处于对数生长期的HK-2细胞,以1×104/孔接种于96孔板中,每孔100μl体系,待24h后细胞达到80%左右将空白组以外的每孔均进行如前文所述的氧糖剥夺处理。弃旧培养基,每孔加入含血清的DMEM/F-12完全培养基,或含不同质量浓度处方提取物(0.125,0.25,0.5,1,2mg·ml-1)的含血清DMEM/F-12完全培养基共孵育24h,干预处理24h后置于倒置光学显微镜下观察细胞形态学变化。
在处方提取物的安全作用质量浓度范围内,给与0.125、0.25、0.5、1、2mg/mL处方提取物,如图16所示,我们发现在光镜下氧糖剥夺所诱导HK-2细胞损伤明显缓解。
实施例6药物组合物在解毒益肾中的研究
1.体外实验(实施例2所得处方提取物)
1.1处方提取物干预TMAO损伤肾小管上皮细胞的蛋白组学分析
我们前期研究证实了处方提取物可以显著改善肾脏损伤,延缓纤维化。为进一步探讨处方提取物调控肾小管上皮细胞损伤抗纤维化的具体机制,我们对处方提取物进行了蛋白组学分析。
我们使用TMAO诱导肾小管上皮细胞损伤,并在该损伤模型下运用处方提取物进行干预,设立空白组、TMAO造模组(TMAO选择40mM/L浓度)、TMAO造模+处方提取物组(选择1mg/ml浓度)三个组别,给药24h后提取细胞蛋白,首先吸弃细胞培养基,使用PBS清洗两遍,加入RIPA裂解液、蛋白酶抑制剂(1/50的比例),混匀裂解15分钟,细胞刮下细胞液,冰浴超声后1200转离心20分钟取上清收集每组细胞蛋白,三组细胞蛋白进行蛋白组学分析。
KEGG通路富集分析显示TMAO主要可以上调脂肪酸合成及p53通路,下调萜类主链合成及糖酵解等通路(图1,2)。而在处方提取物预处理后,肾小管上皮细胞内蛋白亦发生了显著变化。KEGG通路富集分析显示处方提取物干预后可以下调TMAO损伤模型细胞的脂肪酸合成,上调胆固醇及叶酸的代谢、氧化磷酸化等通路(图3,4)。分析结果提示处方提取物可能通过调节脂质代谢相关通路,减轻TMAO的肾脏损伤,结合文献研究提示铁死亡与脂质代谢紊乱及纤维化密切相关,提示肾小管上皮细胞铁死亡可能是处方提取物延缓纤维化的关键治疗靶点。
1.2TMAO诱导肾小管上皮细胞发生铁死亡,处方提取物可以抑制TMAO诱导的肾小管上皮细胞损伤
我们使用梯度浓度的TMAO干预NRK-52E建立肾小管上皮细胞损伤模型,观察细胞形态、数量,MTT检测细胞活性,试剂盒检测细胞内FE、MDA、GSH含量。
将约含8000NRK-52E细胞的5%FBS培养基混悬液接种于96孔板每孔中,每孔100ul。培养箱中孵育24h,待细胞生长至覆盖孔底80%时弃去孔液,以无血清培养基配制梯度浓度的TMAO(0、20、30、40、50、60mmol/L),分组给予肾小管上皮细胞不同的刺激,继续放于培养箱中鮮育24h后,倒置相差显微镜观察细胞形态变化并拍照记录,MTT法检测细胞活性。将细胞接种于6孔板,培养并按实验方案分别给药刺激,同等实验条件下提取细胞内容物及蛋白用于检测细胞内FE、MDA、GSH含量。
结果显示,TMAO能够显著诱导细胞形态变化,数量减少及细胞活性的降低,并且其损伤效果呈一定的浓度依赖性(图5)。TMAO在诱导细胞损伤的同时,能增加细胞内FE和MDA的含量,减少GSH的含量(图6)。
我们使用TMAO诱导肾小管上皮细胞损伤,并在该损伤模型下运用处方提取物进行干预,设立空白组、TMAO造模组(TMAO选择40mM/L浓度)、TMAO造模+处方提取物组(0.5mg/mL、1mg/ml)三个组别,给药24h后MTT法检测细胞活性。将细胞接种于6孔板,培养并按实验方案分别给药刺激,同等实验条件下提取细胞内容物及蛋白用于检测细胞内FE、MDA、GSH含量。
发现其可以显著减轻TMAO诱导的肾小管上皮细胞形态学损伤,提高细胞活性(图7A),抑制ROS产生(图7B),促进SOD酶活性(图7C)。
1.3处方提取物、铁死亡抑制剂Fer1、铁螯合剂DFO可以抑制TMAO诱导的肾小管上皮细胞铁死亡,处方提取物可以抑制RSL3诱导的肾小管上皮细胞铁死亡
(1)使用TMAO诱导NRK-52E建立损伤模型,处方提取物、铁死亡抑制剂Fer1和铁螯合剂DFO进行干预。
将约含8000NRK-52E细胞的5%FBS培养基混悬液接种于96孔板每孔中,每孔100ul。培养箱中孵育24h,待细胞生长至覆盖孔底80%时弃去孔液,选择40mmol/L浓度的TMAO作为造模浓度,以无血清培养基配制Ctrl组、TMAO造模组(40mmol/L)、TMAO+SYJD(1mg/ml)、TMAO+Fer1(5μmol/L)、TMAO+DFO(50μmol/L),给予肾小管上皮细胞不同的刺激,继续放于培养箱中鮮育24h后,倒置相差显微镜观察细胞形态变化并拍照记录,MTT法检测细胞活性。
结果表明,处方提取物、铁死亡抑制剂Fer1和铁螯合剂DFO干预后,发现均可以显著减轻TMAO诱导的肾小管上皮细胞形态学损伤,提高细胞活性(图8)。
(2)使用铁死亡激动剂RSL3诱导NRK-52E发生铁死亡,处方提取物、铁死亡抑制剂Fer1和铁螯合剂DFO干预。
将约含8000NRK-52E细胞的5%FBS培养基混悬液接种于96孔板每孔中,每孔100ul。培养箱中孵育24h,待细胞生长至覆盖孔底80%时弃去孔液,使用0.03μmol/L浓度的铁死亡激动剂RSL3作为造模浓度,以无血清培养基配制Ctrl组、RSL3造模组(0.03μmol/L)、RSL3+SYJD(1mg/ml)、RSL3+Fer1(5μmol/L)、RSL3+DFO(50μmol/L),给予肾小管上皮细胞不同的刺激,继续放于培养箱中鮮育24h后,倒置相差显微镜观察细胞形态变化并拍照记录,MTT法检测细胞活性。
处方提取物、铁死亡抑制剂Fer1和铁螯合剂DFO干预后,发现均可以显著减轻RSL3诱导的肾小管上皮细胞形态学损伤,提高细胞活性(图9)。
2.体内实验(实施例1制备的处方提取物)
2.1TMAO加重肾病大鼠肾脏功能的恶化,处方提取物可以减轻TMAO诱导的肾脏功能恶化
我们选择在腺嘌呤(Ade)诱导的慢性肾衰竭模型的基础上口服1%高胆碱(Cho)饮食,构建高TMAO血症的肾病大鼠模型。DMB是一种TMA合成酶的抑制剂,可以阻断胆碱在肠道内合成TMAO的前体TMA,从而降低胆碱来源的TMAO合成。我们以DMB作为阳性药物对照,以明确是否是TMAO导致了相关肾脏功能指标的变化。
大鼠适应性喂养一周后随机分为6组:对照组(大鼠标准饲料饮食+生理盐水灌胃),腺嘌呤组(腺嘌呤灌胃+标准饲料饮食+生理盐水灌胃),模型组(腺嘌呤灌胃联合高胆碱饲料饮食造模+生理盐水灌胃),阳性药物组(腺嘌呤灌胃联合高胆碱饲料饮食造模+生理盐水灌胃+饮用水中添加阳性药DMB),低剂量处方提取物组(腺嘌呤灌胃联合高胆碱饮食饲料造模+3.3g/kg/d处方提取物灌胃),高剂量处方提取物组(腺嘌呤灌胃联合高胆碱饲料饮食造模+6.6g/kg/d处方提取物灌胃)。造模开始后同时给予SYJD颗粒灌胃、阳性药水饮用6周。所有组均不使用抗生素治疗,各组大鼠灌胃体积均为10ml/kg,每日一次,时间固定。造模开始后第6周禁食12h后留取尿标本,麻醉留取血标本,处死留取肾脏组织标本。
结果显示,相较单纯腺嘌呤模型组,联合服用高胆碱饮食可以进一步提高BUN和SCR水平。而将高胆碱饮食的腺嘌呤模型大鼠联合服用DMB、处方提取物(SYJD)后,均可以显著降低BUN、SCR水平(图10)。在肾脏重量及肾重/体重方面,腺嘌呤模型组大鼠较对照组显著增加,联合高胆碱饮食的腺嘌呤模型大鼠较腺嘌呤模型组进一步上升,而结合服用处方提取物及DMB均可以显著降低肾脏重量及肾重/体重(图11)。结果表明,TMAO可以提高肾病大鼠的血清尿素氮、血清肌酐水平,处方提取物能减轻TMAO诱导的肾脏损伤。
2.2TMAO加重肾脏病理损伤、铁死亡和纤维化,处方提取物可以减轻TMAO诱导的肾脏病理损伤、铁死亡和纤维化。
我们通过Perl’s、Masson染色观察,相较单纯腺嘌呤模型组,联合服用高胆碱饮食可以进一步提高大鼠肾脏铁沉积及纤维化进展,而高胆碱饮食的腺嘌呤模型大鼠联合服用DMB、处方提取物(SYJD)后,均可以显著降低大鼠肾脏铁沉积及纤维化的水平(图12)。结果表明,TMAO可以加重肾病大鼠肾脏铁死亡及纤维化水平,处方提取物能减轻TMAO诱导的肾脏铁死亡及纤维化。
2.3TMAO加重肾脏铁死亡,处方提取物可以改善TMAO诱导的肾脏铁死亡
我们通过试剂盒检测大鼠肾脏铁死亡相关指标IRON、MDA和GSH的含量,结果表明TMAO加重了铁死亡相关指标的变化,而处方提取物及DMB均能改善大鼠肾脏铁死亡的指标(图13)。
2.4TMAO加重肾脏铁死亡及纤维化,处方提取物可以改善TMAO诱导的肾脏铁死亡及纤维化
我们使用Western blot进一步检测肾脏组织铁死亡及纤维化蛋白的表达,结果显示相较单纯腺嘌呤模型组,联合服用高胆碱饮食可以进一步提高大鼠肾脏铁死亡及纤维化蛋白的表达,而高胆碱饮食的腺嘌呤模型大鼠联合服用DMB、处方提取物(SYJD)后,均可以显著降低大鼠肾脏铁死亡及纤维化蛋白的表达水平(图14)。结果表明,TMAO可以加重肾病大鼠肾脏铁死亡及纤维化水平,处方提取物能减轻TMAO诱导的肾脏铁死亡及纤维化。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (17)
1.一种解毒益肾药物组合物,其特征在于,由如下重量份数的中药组分制成:紫苏叶29~37份,茵陈12.5~20.5份,醋五灵脂7~15份,炒蒲黄7~15份,六月雪18~26份,土茯苓29~37份,红花7~15份,酒大黄4.8~12.8份,牡蛎29~37份,茯苓7~15份,黄芪29~37份,酒萸肉或山茱萸7~15份。
2.根据权利要求1所述的药物组合物,其特征在于,所述紫苏叶的重量份数为31~35份。
3.根据权利要求1所述的药物组合物,其特征在于,所述紫苏叶的重量份数为33份。
4.根据权利要求1所述的药物组合物,其特征在于,各中药组分的重量份数如下:紫苏叶31~35份,茵陈14.5~18.5份,醋五灵脂9~13份,炒蒲黄9~13份,六月雪20~24份,土茯苓31~35份,红花9~13份,酒大黄6.8~10.8份,牡蛎31~35份,茯苓9~13份,黄芪31~35份,酒萸肉或山茱萸9~13份。
5.根据权利要求4所述的药物组合物,其特征在于,所述紫苏叶的重量份数为33份。
6.根据权利要求1所述的药物组合物,其特征在于,各中药组分的重量份数如下:紫苏叶33份,茵陈16.5份,醋五灵脂11份,炒蒲黄11份,六月雪22份,土茯苓33份,红花11份,酒大黄8.8份,牡蛎33份,茯苓11份,黄芪33份,酒萸肉或山茱萸11份。
7.根据权利要求1所述的药物组合物,其特征在于,各中药组分的重量份数如下:紫苏叶33g,茵陈16.5g,醋五灵脂11g,炒蒲黄11g,六月雪22g,土茯苓33g,红花11g,酒大黄8.8g,牡蛎33g,茯苓11g,黄芪33g,酒萸肉或山茱萸11g。
8.权利要求1~7中任意一项所述药物组合物的制备方法,其特征在于,将各中药组分加水煎煮两次,过滤,合并滤液;所得滤液浓缩。
9.根据权利要求8所述的制备方法,其特征在于,将牡蛎先加水煎煮20~40min,再加入其他各中药组分煎煮30~50min,过滤,得到第一滤液和第一滤渣;所得滤渣再次加水煎煮30~50min,过滤,得到第二滤液和第二滤渣;将第一滤液和第二滤液混合后,再次过滤,得到第三滤液;所得第三滤液蒸发浓缩,得到浓缩液。
10.根据权利要求9所述的制备方法,其特征在于,包括如下步骤:所述浓缩液冷冻干燥,得到干粉。
11.根据权利要求10所述的制备方法,其特征在于,还包括如下步骤:将所述干粉用PBS缓冲液溶解,再次过滤,得到滤液。
12.根据权利要求8所述的制备方法,其特征在于,将各中药组分加水煎煮两次,每次30~50min,过滤,所得滤液浓缩至相对密度为1.10~1.20的浓缩液。
13.根据权利要求12所述的制备方法,其特征在于,包括如下步骤:将糊精置于流化床中,当物料升温至70~80℃时,开始进液,雾化,干燥,即得。
14.根据权利要求13所述的制备方法,其特征在于,所述进液的速度为80~150r/min;
所述雾化的外压力为0.15~0.25MPa;所述雾化的内压力为0.1~0.2MPa。
15.权利要求1~7中任意一项所述药物组合物在制备解毒益肾药物中的应用.
16.权利要求1~7中任意一项所述药物组合物在制备防治慢性肾脏病药物中的应用,或在制备防治肾小管上皮细胞损伤或死亡药物中的应用,或在制备防治肾脏功能恶化、肾脏病理损伤、肾脏铁死亡、或肾脏纤维化药物中的应用。
17.权利要求1~7中任意一项所述药物组合物在制备铁死亡抑制剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310750510.XA CN116585432B (zh) | 2023-06-25 | 2023-06-25 | 一种药物组合物及其制备方法与在制备解毒益肾药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310750510.XA CN116585432B (zh) | 2023-06-25 | 2023-06-25 | 一种药物组合物及其制备方法与在制备解毒益肾药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116585432A CN116585432A (zh) | 2023-08-15 |
CN116585432B true CN116585432B (zh) | 2023-12-15 |
Family
ID=87595814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310750510.XA Active CN116585432B (zh) | 2023-06-25 | 2023-06-25 | 一种药物组合物及其制备方法与在制备解毒益肾药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116585432B (zh) |
-
2023
- 2023-06-25 CN CN202310750510.XA patent/CN116585432B/zh active Active
Non-Patent Citations (4)
Title |
---|
"益肾解毒汤"联合中药长程间歇灌肠治疗慢性肾脏病3―4期30例临床研究;束洋 等;江苏中医药;47(11);29-31 * |
周恩超教授从毒论治慢性肾衰竭常用药对介绍;尹浩 等;浙江中医药大学学报;第40卷(第12期);932-935 * |
周恩超益肾解毒法分期治疗慢性肾衰竭验案撷萃;祝一叶 等;浙江中医药大学学报;第43卷(第9期);971-974 * |
尹浩 等.周恩超教授从毒论治慢性肾衰竭常用药对介绍.浙江中医药大学学报.2016,第40卷(第12期),932-935. * |
Also Published As
Publication number | Publication date |
---|---|
CN116585432A (zh) | 2023-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102940779B (zh) | 一种治疗慢性溃疡性结肠炎的药物组合物及其制备方法 | |
WO2008037222A1 (en) | A hypolipidemic composition and its use | |
CN102430015B (zh) | 一种治疗肾炎及尿毒症的中药制剂及其制备方法 | |
CN116585432B (zh) | 一种药物组合物及其制备方法与在制备解毒益肾药物中的应用 | |
CN100528186C (zh) | 一种治疗慢性肾功能衰竭中药复方注射剂的制备工艺以及应用 | |
CN107519430A (zh) | 一种治疗原发性胆汁性肝硬化的中药组合物及其制备方法和应用 | |
CN104490904B (zh) | 一种治疗神经衰弱的药物组合物及其制备方法 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN102861192B (zh) | 用于慢性肾功能衰竭和腹膜纤维化的药物组合物 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN105055708A (zh) | 一种用于治疗肾炎的药物 | |
CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
CN103735906A (zh) | 一种治疗干性支气管扩张的中药制剂及其制备方法 | |
CN103656355B (zh) | 用于治疗猪副伤寒的药物及其制备方法 | |
CN113769046B (zh) | 一种治疗肠化生的中药组合物、制备方法和应用 | |
CN114848730B (zh) | 一种治疗急性浆细胞乳腺炎的复方中药组合物的制备及应用 | |
CN116650600B (zh) | 一种用于防治高尿酸血症及痛风的四药中药组合物、方法及应用 | |
CN105213975A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN108853380B (zh) | 治疗糖尿病的药物组合物及其制备方法和应用 | |
CN104771705A (zh) | 一种治疗慢性肾炎的中药剂 | |
CN106177250A (zh) | 一种治疗慢性肾炎的中药组合物 | |
CN105456447A (zh) | 一种含有艾叶的具有活血化淤功能的中药组合物及其制备方法 | |
CN105943860A (zh) | 一种用于治疗糖尿病的药物制剂及其制备方法 | |
CN105055665A (zh) | 一种抗肝癌的中药制剂 | |
CN104524149A (zh) | 一种防治急性肾炎的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |